Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin:: involvement of KATP channels

被引:47
作者
Freiman, TM
Kukolja, J
Heinemeyer, J
Eckhardt, K
Aranda, H
Rominger, A
Dooley, DJ
Zentner, J
Feuerstein, TJ
机构
[1] Univ Freiburg, Neurol Klin, Neurozentrum, Sekt Klin Neuropharmakol, D-79106 Freiburg, Germany
[2] Univ Freiburg, Neurochirurg Klin, Neurozentrum, D-79106 Freiburg, Germany
[3] Pfizer Global Res & Dev, Dept CNS Pharmacol, Ann Arbor, MI 48105 USA
关键词
gabapentin; K-ATP channel; noradrenaline; epilepsy; anticonvulsants;
D O I
10.1007/s002100100408
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To elucidate the mechanism of action of the anticonvulsant gabapentin (GBP), we compared its effects on K+-evoked [H-3]-noradrenaline ([H-3]-NA) release from rat hippocampal and human neocortical slices with those of the K-ATP channel opener pinacidil and the Na+ channel blockers phenytoin, carbamazepine and lamotrigine. Rat hippocampal and human neocortical slices were loaded with [H-3]-NA and superfused. [H-3]-NA release was evoked by increasing the extracellular [K+] from 3 to 15 mM. GBP decreased [H-3]-NA release from rat hippocampal with a pIC(50) of 5.59 and a maximum inhibition of 44%. Concentration-dependent inhibition was also seen in human neocortical slices (39% inhibition with 100 muM GBP). These inhibitory effects were antagonized by the K, channel antagonist glibenclamide, yielding a pA(2) of 7.50 in the rat. The K-ATP channel opener pinacidil (10 muM), like GBP, decreased [H-3]-NA release from rat hippocampal slices by 27% and this effect was also antagonized by glibenclamide. In human neocortical slices the inhibition by pinacidil (10 muM) was 31%. Although phenytoin (10 muM), carbamazepine (100 muM) and lamotrigine (10 muM) also decreased [H-3]-NA release (by 25%, 57% and 22%, respectively), gribenclamide did not antagonize the effects of these classical Na+ channel blockers. These findings suggest that GBP inhibits K+-evoked [H-3]-NA release through activation of K-ATP channels. To establish whether the K-ATP channels under investigation were located on noradrenegic nerve terminals or on other neuronal elements, the effects of GBP were compared in the absence and in the presence of tetrodotoxin (TTX 0.32 muM) throughout superfusion. Since the functional elimination of the perikarya of interneurons by TTX reduced the inhibitory effect of GBP, the K-ATP channels mediating the effect of GBP may be located on nerve terminals, probably on both noradrenergic and glutamatergic nerve endings.
引用
收藏
页码:537 / 542
页数:6
相关论文
共 46 条
[1]   STATISTICS IN MEDICAL JOURNALS - DEVELOPMENTS IN THE 1980S [J].
ALTMAN, DG .
STATISTICS IN MEDICINE, 1991, 10 (12) :1897-1913
[2]   ACTIONS OF BRL-34915 (CROMAKALIM) UPON CONVULSIVE DISCHARGES IN GUINEA-PIG HIPPOCAMPAL SLICES [J].
ALZHEIMER, C ;
TENBRUGGENCATE, G .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1988, 337 (04) :429-434
[3]   GABAPENTIN (NEURONTIN) AS ADD-ON THERAPY IN PATIENTS WITH PARTIAL SEIZURES - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
ANHUT, H ;
ASHMAN, P ;
FEUERSTEIN, TJ ;
SAUERMANN, W ;
SAUNDERS, M ;
SCHMIDT, B ;
BAUER, G ;
DEISENHAMMER, E ;
KLINGLER, D ;
MAMOLI, B ;
GRAF, M ;
DANTA, G ;
BERKOVIC, S ;
VAJDA, F ;
BUCHANAN, N ;
SCHAPEL, G ;
BLACK, A ;
BAJADA, S ;
DEBARSY, T ;
LATERRE, C ;
VANZANDIJCKE, M ;
MCLACHLAN, RS ;
PURVES, SJ ;
LEE, MA ;
BRUNI, J ;
GAWEL, M ;
HOLTLARSEN, B ;
WERDELIN, L ;
DALBY, MA ;
IIVANAINEN, MV ;
GIROUD, M ;
LECLERCQ, E ;
REMY, C ;
SALLOU, C ;
RICHENS, A ;
BILL, PLA .
EPILEPSIA, 1994, 35 (04) :795-801
[4]   LONG-TERM SAFETY AND EFFICACY OF GABAPENTIN (NEURONTIN) AS ADD-ON THERAPY IN PATIENTS WITH REFRACTORY PARTIAL SEIZURES [J].
ANHUT, H ;
ASHMAN, PJ ;
FEUERSTEIN, TJ ;
QUEBEFEHLING, E ;
SAUNDERS, M ;
BARON, BA ;
BAUER, G ;
DEISENHAMMER, E ;
KLINGLER, D ;
MAMOLI, B ;
GRAF, M ;
DANTA, G ;
VAJDA, F ;
BUCHANAN, N ;
SCHAPEL, GJ ;
BLACK, A ;
BAJADA, S ;
DEBARSY, T ;
LATERRE, C ;
VANZANDIJCKE, M ;
MCLACHLAN, RS ;
PURVES, SJ ;
LEE, MA ;
BRUNI, J ;
GAWEL, M ;
HOLTLARSEN, B ;
WERDELIN, L ;
DALBY, MA ;
IIVANAINEN, MV ;
RIEKINNEN, PJ ;
SIVENIUS, JMR ;
LECLERCQ, E ;
REMY, C ;
SALLOU, C ;
BILL, PLA ;
PERSSON, LI ;
SODERFELDT, B ;
RICHENS, A .
JOURNAL OF EPILEPSY, 1995, 8 (01) :44-50
[5]   Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus [J].
Backonja, MM .
EPILEPSIA, 1999, 40 :S57-S59
[6]   SELECTED CSF BIOCHEMISTRY AND GABAPENTIN CONCENTRATIONS IN THE CSF AND PLASMA IN PATIENTS WITH PARTIAL SEIZURES AFTER A SINGLE ORAL DOSE OF GABAPENTIN [J].
BENMENACHEM, E ;
PERSSON, LI ;
HEDNER, T .
EPILEPSY RESEARCH, 1992, 11 (01) :45-49
[7]   Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy [J].
Beydoun, A ;
Fakhoury, T ;
Nasreddine, W ;
Abou-Khalil, B .
EPILEPSIA, 1998, 39 (02) :188-193
[8]  
CHEUNG H, 1992, EPILEPSY RES, V13, P107
[9]   Spermine modulation of specific [H-3]-gabapentin binding to the detergent-solubilized porcine cerebral cortex alpha(2)delta calcium channel subunit [J].
Dissanayake, VUK ;
Gee, NS ;
Brown, JP ;
Woodruff, GN .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (05) :833-840
[10]  
Dooley DJ, 2000, J PHARMACOL EXP THER, V295, P1086